OmniPod ENT450 - General Warnings and Cautions

xi
IntroductionIntroduction
General Warnings and Cautions
Warnings:
Rapid-acting U-100 insulin: e Omnipod® System is designed to use
rapid-acting U-100 insulin. e following U-100 rapid-acting insulin
analogs have been tested and found to be safe for use in the Pod: NovoRapid®,
Humalog®, or Apidra®. NovoRapid®, Humalog, and Apidra are compatible
with the Omnipod® System for use up to 72 hours (3 days). Before using a
dierent insulin with the Omnipod® System, check the insulin drug label to
make sure it can be used with a pump. Refer to the insulin labeling and follow
your healthcare provider’s directions for how oen to replace the Pod.
Read all the instructions provided in this User Guide and practice the
blood glucose testing procedures before using the System. Monitor your
blood glucose with the guidance of your healthcare provider. Undetected
hyperglycemia or hypoglycemia can result without proper monitoring.
Warnings:
Personal health considerations
Not recommended for individuals with hearing loss. Always verify your
ability to hear Pod/PDM alarms and notications.
If you are unable to use the System according to instructions, you may be
putting your health and safety at risk. Talk with your healthcare provider if
you have questions or concerns about using the System properly.
Parts of the device are considered biohazardous and can potentially transmit
infectious diseases, even aer you have performed cleaning and disinfection.
e glucose meter and lancing device are for single-patient use. Do not share
the device with anyone including other family members. Do not use on
multiple patients.